Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte
WASHINGTON, DC — While Incyte and the founders of Flexus scrap in court over who owns the IDO1 technology that Bristol-Myers Squibb $BMY bought in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
